Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902664-24-001615
Filing Date
2024-02-14
Accepted
2024-02-14 09:22:12
Documents
1

Document Format Files

Seq Description Document Type Size
1 ALPINE IMMUNE SCIENCES, INC. p24-0770sc13ga.htm SC 13G/A 59658
  Complete submission text file 0000902664-24-001615.txt   61488
Mailing Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102
Business Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102 206-788-4545
ALPINE IMMUNE SCIENCES, INC. (Subject) CIK: 0001626199 (see all company filings)

EIN.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-88896 | Film No.: 24633043
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 151 CALLE DE SAN FRANCISCO SUITE 200 PMB 1237 SAN JUAN PR 00901-1607
Business Address 151 CALLE DE SAN FRANCISCO SUITE 200 PMB 1237 SAN JUAN PR 00901-1607 703-963-7214
Lynx1 Capital Management LP (Filed by) CIK: 0001910456 (see all company filings)

EIN.: 851134656 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A